{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:09Z","timestamp":1788013089937,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s43441-026-01010-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:54:38Z","timestamp":1782867278000},"page":"1542-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-3756","authenticated-orcid":false,"given":"Revathi","family":"Ananthakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8778-954X","authenticated-orcid":false,"given":"Gu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5327-086X","authenticated-orcid":false,"given":"Gina","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-1501","authenticated-orcid":false,"given":"Philip","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"1010_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08440-0","volume":"21","author":"K Brock","year":"2021","unstructured":"Brock K, Homer V, Soul G, Potter C, Chiuzan C, Lee S. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. BMC Cancer. 2021;21(1):777.","journal-title":"BMC Cancer"},{"issue":"5","key":"1010_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/1078-0432.CCR-23-2268","volume":"30","author":"G Collins","year":"2024","unstructured":"Collins G, McKelvey B, Andrews HS, Allen JD, Stewart MD. An Analysis of dosing-related postmarketing requirements for novel oncology drugs approved by the U.S. food and drug administration. Clin Cancer Res. 2024;30(5):937\u201341.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1010_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pst.70044","volume":"24","author":"G D\u2019Angelo","year":"2025","unstructured":"D\u2019Angelo G, Chen G, Ran D. Utility-based dose optimization approaches for multiple-dose randomized trial designs accounting for multiple endpoints. Pharm Stat. 2025;24(6):e70044.","journal-title":"Pharm Stat"},{"issue":"2","key":"1010_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/19466315.2024.2365630","volume":"17","author":"G D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo G, Gong M, Marshall J, Yuan Y, Li X. U-MET: utility-based dose optimization approach for multiple-dose randomized trial designs. Stat Biopharm Res. 2024;17(2):211\u201321.","journal-title":"Stat Biopharm Res"},{"key":"1010_CR5","unstructured":"U.S. Food and Drug Administration. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry. U.S. Department of Health and Human Services; August 2024. https:\/\/www.fda.gov\/media\/164555\/download."},{"key":"1010_CR6","unstructured":"U.S. Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. U.S. Department of Health and Human Services; November 2019. https:\/\/www.fda.gov\/media\/78495\/download."},{"key":"1010_CR7","doi-asserted-by":"crossref","unstructured":"Geller NL, Follman D, Leifer ES, Carter SL. Design of early trials in stem cell transplantation: a hybrid frequentist-Bayesian approach. Adv Clinic Trial Biostat. 2003","DOI":"10.1201\/9780203912881.ch2"},{"key":"1010_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115593","volume":"226","author":"A Glasmacher","year":"2025","unstructured":"Glasmacher A, Garralda E, Gwaltney C, Rupalla K, Li C, Weber H. Dose optimization in cancer drug development: review and outcome of a multi-stakeholder workshop. Eur J Cancer. 2025;226:115593.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1010_CR9","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1111\/biom.13840","volume":"79","author":"B Guo","year":"2023","unstructured":"Guo B, Yuan Y. DROID: dose-ranging approach to optimizing dose in oncology drug development. Biometrics. 2023;79(4):2907\u201319.","journal-title":"Biometrics"},{"key":"1010_CR10","unstructured":"He P, Mi G, Zhang Z, Chakravartty A, Mitchell P, D\u2019Angelo G, Ma H, Mishra K, Colin P. Book chapter: oncology dose optimization trials. In: Statistics in clinical development of cancer drugs: recent trends & advances. In Press. Springer; 2025."},{"issue":"16_suppl","key":"1010_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1200\/JCO.2023.41.16_suppl.1598","volume":"41","author":"B Heiss","year":"2023","unstructured":"Heiss B, Pan L, Akalu A, Vallejo J, Cheng J, Balcazar P, et al. Dosage optimization in drug development: an FDA project optimus analysis of postmarketing requirements issued to repair the cracks. J Clin Oncol. 2023;41(16_suppl):1598\u20131598.","journal-title":"J Clin Oncol"},{"key":"1010_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114204","volume":"208","author":"M Hochmair","year":"2024","unstructured":"Hochmair M, Vermaelen K, Mountzios G, Carcereny E, Dooms C, Lee S, et al. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. Eur J Cancer. 2024;208:114204.","journal-title":"Eur J Cancer"},{"key":"1010_CR13","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1016\/j.xphs.2024.10.002","volume":"113","author":"Q Hu","year":"2024","unstructured":"Hu Q, Wang L, Yang Y, Lee J. Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: a focus on exposure-response analyses. J Pharm Sci. 2024;113:3434\u201346.","journal-title":"J Pharm Sci"},{"key":"1010_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","volume":"61","author":"A Ivanova","year":"2005","unstructured":"Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005;61:540\u20135.","journal-title":"Biometrics"},{"key":"1010_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906251","volume":"12","author":"M Jiang","year":"2022","unstructured":"Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022;12:906251.","journal-title":"Front Oncol"},{"key":"1010_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107278","volume":"132","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Mi G, Lin J, Lorenzato C, Ji Y. A multi-arm two-stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials. Contemp Clin Trials. 2023;132:107278.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"1010_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/cpt.3353","volume":"116","author":"B Kiesel","year":"2024","unstructured":"Kiesel B, Osawa M, Masilamani M, Bar M, Hsu K, Godwin C, et al. Informing the recommended phase III dose of Alnuctamab, a CD3\u2009\u00d7\u2009BCMA T-cell engager, using population pharmacokinetics and exposure-response analysis. Clin Pharmacol Ther. 2024;116(3):866\u201374.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1010_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s43441-024-00652-3","volume":"58","author":"D Li","year":"2024","unstructured":"Li D, Xu Z, Wen S, Ananthakrishnan R, Kim Y, Rantell KR, et al. Challenges and lessons learned in autologous chimeric antigen receptor T-cell therapy development from a statistical perspective. Ther Innov Regul Sci. 2024;58(5):817\u201330.","journal-title":"Ther Innov Regul Sci"},{"issue":"18","key":"1010_CR19","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/sim.10129","volume":"43","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang Y, Mi G, Lin J. A seamless phase II\/III design with dose optimization for oncology drug development. Stat Med. 2024;43(18):3383\u2013402.","journal-title":"Stat Med"},{"key":"1010_CR20","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.conctc.2024.101329","volume":"40","author":"JJZ Liao","year":"2024","unstructured":"Liao JJZ, et al. Three steps toward dose optimization for oncology dose finding. Contemp Clinic Trials Commun. 2024;40:101329.","journal-title":"Contemp Clinic Trials Commun"},{"issue":"1","key":"1010_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxae034","volume":"26","author":"M Lu","year":"2025","unstructured":"Lu M, Yuan Y, Liu S. A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimes. Biostatistics. 2025;26(1):kxae034.","journal-title":"Biostatistics"},{"issue":"5","key":"1010_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/clpt.2014.153","volume":"96","author":"L Minasian","year":"2014","unstructured":"Minasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky RL. Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014;96(5):572\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1010_CR23","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/cpt.3611","volume":"117","author":"S Mita","year":"2025","unstructured":"Mita S, Ono S. Dose determinations at drug approval reviews: FDA-approved drugs in past 5 years. Clin Pharmacol Ther. 2025;117(6):1743\u201353.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1010_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12793\/tcp.2022.30.e9","volume":"30","author":"H Moon","year":"2022","unstructured":"Moon H. FDA initiatives to support dose optimization in oncology drug development: the less may be the better. Transl Clin Pharmacol. 2022;30(2):71\u20134.","journal-title":"Transl Clin Pharmacol"},{"key":"1010_CR25","unstructured":"U.S. Food and Drug Administration. Project Optimus. Oncology Center of Excellence. Content current as of December 6, 2024. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Accessed 28 June 2026."},{"key":"1010_CR26","first-page":"1","volume":"5","author":"A Renner","year":"2019","unstructured":"Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol. 2019;5:1\u20135.","journal-title":"J Glob Oncol"},{"issue":"25","key":"1010_CR27","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Saito","year":"2020","unstructured":"Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K. DESTINY-Gastric01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"2","key":"1010_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2444","volume":"24","author":"H Sun","year":"2025","unstructured":"Sun H, Tu J. PKBOIN-12: a bayesian optimal interval phase I\/II design incorporating pharmacokinetics outcomes to find the optimal biological dose. Pharm Stat. 2025;24(2):e2444.","journal-title":"Pharm Stat"},{"issue":"10","key":"1010_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"E Wang","year":"2024","unstructured":"Wang E, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25(10):1310\u201324.","journal-title":"Lancet Oncol"},{"key":"1010_CR30","doi-asserted-by":"crossref","unstructured":"Wang S, Yuan Y, Liu S. ROSE: randomized optimal selection design for dose optimization. Biometrics, in press; 2025","DOI":"10.1093\/biomtc\/ujaf124"},{"issue":"3","key":"1010_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/19466315.2023.2292816","volume":"16","author":"Z Yu","year":"2024","unstructured":"Yu Z, Wang Y, Lin J. DODII: Bayesian dose optimization design for randomized phase II trials. Stat Biopharm Res. 2024;16(3):294\u2013304.","journal-title":"Stat Biopharm Res"},{"issue":"12","key":"1010_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122180","volume":"16","author":"ME Zettler","year":"2024","unstructured":"Zettler ME. Dose optimization of targeted therapies for oncologic indications. Cancers (Basel). 2024;16(12):2180.","journal-title":"Cancers (Basel)"},{"key":"1010_CR33","doi-asserted-by":"publisher","unstructured":"Zhang F, Broglio K, Sweeting M, D'Angelo G. CUI-MET: A clinical utility index based analysis and decision framework for dose optimization in multiple-dose, multiple-outcome randomized trials. Pharma Stat. 2026;25(4):e70101. https:\/\/doi.org\/10.1002\/pst.70101.","DOI":"10.1002\/pst.70101"},{"key":"1010_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/17407745251350596","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Liu R, Lin J, Yuan Y. BARD: a seamless two-stage dose optimization design integrating backfill and adaptive randomization. Clin Trials. 2025. https:\/\/doi.org\/10.1177\/17407745251350596.","journal-title":"Clin Trials"},{"issue":"11","key":"1010_CR35","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/sim.9337","volume":"41","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, et al. TITE-BOIN12: a Bayesian phase I\/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022;41(11):1918\u201331.","journal-title":"Stat Med"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01010-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:07Z","timestamp":1788011227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-01010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01010-1","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RA is an employee of Bristol Myers Squibb and may own its stocks. PM and GD are employees of AstraZeneca and may have stock ownership, options, or interests in the company. DX is an employee of and owns stock in Gilead. YW is an employee of Oncolytics Biotech Inc. and may own its stocks. HM is an employee of Revolution Medicines and may own its stocks. GM is an employee of Sanofi and may own its stocks. PH is an employee of Daiichi Sankyo Inc and may own its stocks.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We don\u2019t have any ethics declarations.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Please note that the views and opinions expressed in this paper are those of the authors and are not intended to reflect the views and\/or opinions of their employer(s).","order":3,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}